By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Revance Therapeutics, Inc. 

7555 Gateway Boulevard

Newark  California  94560  U.S.A.
Phone: 510-742-3400 Fax: 510-742-3401


Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

Key Statistics

Ownership: Public

Web Site: Revance
Employees: 100+
Symbol: RVNC

Company News
Revance (RVNC) To Release First Quarter 2017 Financial Results Tuesday, May 9, 2017 4/26/2017 7:06:33 AM
Revance (RVNC) Completes Enrollment In Phase III Pivotal Trials Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines 3/7/2017 6:44:04 AM
Revance (RVNC) Announces BELMONT Phase II Clinical Data To Be Presented At The 2017 American Academy of Dermatology (AAD) Annual Meeting 3/3/2017 7:11:17 AM
Revance (RVNC) Releases Fourth Quarter And Full Year 2016 Results 2/28/2017 7:11:31 AM
Revance (RVNC) To Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017 2/17/2017 6:46:19 AM
Revance (RVNC) Announces Positive 24-Week Duration Of Effect In Interim Results From Phase 2 Cervical Dystonia Trial 12/13/2016 11:30:34 AM
Revance (RVNC) Announces Initiation Of Subject Dosing In The SAKURA Phase III Clinical Program Of RT002 Injectable For The Treatment Of Glabellar (Frown) Lines 12/7/2016 8:40:08 AM
Revance (RVNC) Releases Third Quarter 2016 Results 11/4/2016 10:58:06 AM
Revance (RVNC) Announces Initiation Of Phase II Trial Of RT002 Injectable To Treat Plantar Fasciitis 11/3/2016 11:27:39 AM
Revance (RVNC) To Release Third Quarter 2016 Financial Results Thursday, November 3, 2016 10/25/2016 10:44:38 AM